Clinical Trials

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT02902029 2025-04-09

ImmunoCobiVem

186 enrolled

Phase 2 Active not recruiting

Melanoma

NCT04722575 2025-03-13

NEO-TIM

95 enrolled

Phase 2 Active not recruiting

Melanoma

NCT03224767 2025-02-18

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

24 enrolled

CNS

Craniopharyngioma

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

25 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Active not recruiting

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04185831 2024-08-22

MEGALiT

167 enrolled

Other solid neoplasm

Solid Tumor

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

250 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT03395899 2024-06-18

ECLIPSE

71 enrolled

Breast

Breast Neoplasms

NCT03625141 2024-04-11

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

80 enrolled 20 charts

Melanoma

NCT03201458 2024-04-05

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

86 enrolled 16 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT05756556 2024-02-01

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Phase 2 Suspended

68 enrolled

Melanoma

NCT04591431 2023-10-03

ROME

BreastGastrointestinalThoracic

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03430947 2023-09-14

RadioCoBRIM

20 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03363867 2023-08-07

BEACON

30 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

169 enrolled 31 charts

Breast

Breast Neoplasms

NCT02414750 2022-11-30

REPOSIT

78 enrolled

Melanoma

NCT02036086 2022-10-27

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

24 enrolled

Melanoma

NCT03264066 2021-05-11

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

87 enrolled 24 charts

Other solid neoplasm

Solid Tumors

NCT03224208 2021-04-26

VECODUE

9 enrolled

Melanoma

NCT02303951 2021-02-03

NEO-VC

47 enrolled

Melanoma

NCT02968303 2020-06-05

COWBOY

200 enrolled

Sarcoma

Sarcoma, Clear Cell

NCT02537600 2020-01-27

CONVERCE

43 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02768207 2019-08-28

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

40 enrolled

Melanoma

NCT01813214 2019-02-26

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

5 enrolled 7 charts

Melanoma

NCT03340558 2018-10-09

ATELIER

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01495988 2017-10-24

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

10 enrolled 10 charts